The Adenosine Pathway and Human Immunodeficiency Virus-Associated Inflammation

Emily A. Hixson,1,4 Priya V. Borker,1,2 Edwin K. Jackson3 and Bernard J. Macatangay1,4

1Department of Infectious Disease and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania, USA, 2Division of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA, 3Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA, 4Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pennsylvania, USA

Human immunodeficiency virus (HIV) is associated with an increased risk of age-associated comorbidities and mortality compared to people without HIV. This has been attributed to HIV-associated chronic inflammation and immune activation despite viral suppression. The adenosine pathway is an established mechanism by which the body regulates persistent inflammation to limit tissue damage associated with inflammatory conditions. However, HIV infection is associated with derangements in the adenosine pathway that limits its ability to control HIV-associated inflammation. This article reviews the function of purinergic signaling and the role of the adenosine signaling pathway in HIV-associated chronic inflammation. This review also discusses the beneficial and potential detrimental effects of pharmacotherapeutic strategies targeting this pathway among people with HIV.

Keywords. adenosine; HIV; inflammation, non-AIDS comorbidities; purinergic signaling.

Despite viral suppression on antiretroviral therapy (ART), human immunodeficiency virus (HIV) has been associated with elevated levels of systemic inflammation and immune activation, which accompanies an increased risk of morbidity and mortality from non-acquired immunodeficiency syndrome (AIDS)-associated chronic diseases [1, 2]. People with HIV (PWH) experience accelerated immunologic aging and develop cardiovascular disease (CVD), liver disease, and non-AIDS-defining cancers earlier than people without HIV (PWOH) of similar age [3, 4].

In a recent study, purinergic signaling has been implicated in regulating the immunopathogenesis of HIV [5, 6]. Purinergic receptor activation impacts phagocytosis, antigen presentation, cytotoxicity, chemotaxis, chemokine and cytokine release, and T lymphocyte differentiation [7, 8]. Therefore, tailoring pharmacotherapeutic interventions to target purinergic signaling could be an important strategy in regulating chronic inflammation and persistent immune activation associated with chronic HIV. This review highlights (1) the immunologic importance of adenosine triphosphate (ATP) and its nucleoside, adenosine, in modulating the immunologic response and inflammation in chronic HIV infection and (2) the potential role of purinergic receptor-targeted therapies in the prevention and treatment of the chronic disease events seen in PWH.

THE IMMUNOLOGIC FUNCTION OF ADENOSINE

The relationship between extracellular ATP to adenosine is a major local signal of immunooactivation versus immunosurveillance, which is governed by extracellular and intracellular purinergic metabolism (Figure 1). In response to stress, large amounts of ATP are actively and passively released into the extracellular space. Adenosine triphosphate acts as a damage-associated molecular pattern (DAMP) and activates type 2 purinergic (P2) receptors [9]. The P2 receptors consist of 2 main subtypes, P2X and P2Y receptors. The P2X receptors are ATP-gated ionotropic channels that are generally involved in proinflammatory processes. In particular, P2X, stimulation causes further ATP release that triggers a positive feedback loop to amplify the ATP signal while recruiting appropriate cells to the area [10]. The P2Y receptors are G-protein-coupled receptors that are implicated in a broad range of functions, including facilitating platelet aggregation, vasodilation, cell migration, and immune responses [11].

Extracellular ATP is catabolized into adenosine 5'-monophosphate (5'-AMP) by a family of enzyme ectonucleotidases, the most important being dephosphorylase-1 (CD39). Subsequently, 5'-AMP is converted to adenosine mainly by ecto-5'-nucleotidase (CD73) and other tissue nonspecific alkaline phosphatases [12]. Extracellular adenosine can be further metabolized to a proinflammatory substrate, inosine, via adenosine deaminase or be transported intracellularly.
via equilibrative nucleoside transporters (ENTs) [13, 14]. Extracellular adenosine activates type 1 purinergic (P1) receptors, which consists of subtypes A<sub>1</sub>, A<sub>2A</sub>, A<sub>3</sub>, and A<sub>4</sub> that modulate adenylyl cyclase and the 3′5′-cyclic monophosphate pathway [15]. The A<sub>1</sub> receptor is ubiquitous throughout the human body and typically has a proinflammatory effect [16]. However, A<sub>4</sub> receptors exhibit an anti-inflammatory role [17]. Specifically, activating the A<sub>2A</sub> receptor suppresses neutrophil responses [18, 19], monocyte and macrophage recruitment as well as macrophage phagocytic function [20], and proinflammatory cytokine secretion [21, 22]. A<sub>2A</sub> receptor agonists interfere with T-cell receptor signaling and suppress T-cell proliferation and effector function [23], ultimately producing anergic T cells [24, 25].

Constitutively low levels of extracellular ATP and adenosine are maintained by nucleoside and purine transporters under normal physiological conditions [26]. On most cells, including lymphocytes and endothelial cells, the surface expression of CD39 and CD73 is regulated by external stimuli that ultimately influence the concentration of adenosine in the local environment to mediate paracrine signaling [27]. The concentrations of extracellular ATP and adenosine are intrinsically regulated during inflammation and immune responses, which modulates the functions of myeloid and lymphoid cells [28]. During acute inflammatory responses, high levels of extracellular ATP act as a DAMP and trigger proinflammatory effector functions in a setting of low extracellular adenosine levels, including T lymphocyte migration and proliferation [29]. In the ATP-rich,
adenosine-poor environment, A_2 receptors work synergistically with P2 receptors to promote cell migration, cytotoxicity, apoptosis, and proinflammatory cytokine secretion in neutrophils [30], monocytes [31, 32], and macrophages [33, 34].

As inflammation persists, the concentration of extracellular adenosine increases as a result of the breakdown of ATP [35, 36]. Immune cells in the most injured areas produce an adenosine-rich environment to inhibit themselves, and other local immune cells, while allowing neighboring cells to continue eliminating the pathogen [37]. The protective increase in extracellular adenosine inhibits effector functions of neutrophils, macrophages, dendritic cells, and T lymphocytes [28]. Thus, a rise in extracellular adenosine and A_2A receptor expression provides a negative feedback mechanism to prevent further tissue damage [38]. These characteristics, combined with the short half-life of adenosine in vivo, allow for efficient paracrine and autocrine adenosine signaling among immune cells [39].

THE ADENOSINE PATHWAY IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION

Given the established ability of the adenosine pathway in modulating immune function, multiple studies have examined the relationship between adenosine and HIV (Table 1). Specifically, antagonism of the P2X receptor inhibits HIV infection of CD4+ T lymphocytes [52]. For example, CD34+ hematopoietic progenitor cells from PWH who are immunologic nonresponders (INRs) overexpress P2X,R, and inhibition of these receptors promotes maturation of CD4+ T cells [51]. Moreover, macrophages, which can act as HIV reservoirs, release HIV-1 virions from stored vacuoles when stimulated with P2X,R agonists [53]. Human immunodeficiency virus infection directly impairs purinergic metabolism on inflammatory immune cells, which skews towards an adenosine-poor local environment, thereby promoting chronic immune activation [6]. In our study comparing CD39 and CD73 expression on Tregs, we found higher frequencies of ectonucleotidase coexpression as well as higher levels of adenosine in gut mucosal tissue in the nonprogressive model of simian immunodeficiency virus (SIV) infection in African green monkeys (AGM) compared with the progressive model in pigtailed macaques (PTM) [5]. This finding suggests a potential role for adenosine in AGM through the control of immune activation and inflammation, despite SIV infection, that prevents them from progressing to AIDS. When examining the functionality of adenosine ex vivo, we found that adenosine significantly suppressed cytokine production of CD4+ and CD8+ T cells in both AGM and PTM [5].

In addition to chronic immune activation, changes to the purinergic pathway during HIV infection are associated with T-cell exhaustion, immunosenescence, and immunosuppression, which mitigates the ability of the immune system to effectively manage chronic viral infection or cancer [54–56]. Human immunodeficiency virus infection is associated with the downregulation of CD73 and upregulation of CD39 on CD8+ T cells, the latter of which has been identified as a marker of terminal exhaustion [50, 57]. Among viremic PWH, there is greater CD39, but not CD73, expression in natural killer cells, which correlates with viral load and markers of systemic inflammation [58].

Although the adenosine pathway could be protective in HIV-associated chronic inflammation and immune activation, its immunosuppressive function could have important implications in HIV persistence. Regulatory T cells (Tregs) represent important viral reservoirs during chronic HIV infection, and the frequency of CD39+ Tregs is correlated with Treg HIV deoxyribonucleic acid levels [59]. The Treg cells coexpress CD39 and CD73, which make them highly efficient in generating adenosine [60]. Because CD39 expression is upregulated in Tregs for PWH, this creates an adenosine-Treg positive feedback loop to promote a local adenosine-rich, immunosuppressant environment [48]. In addition, A_2A receptor activation increases Treg suppressive activity [25, 61, 62]. There is evidence in vitro that CD4+CD25+ Tregs in ART-treated PWH diminishes CD4+ and CD8+ T-cell function and proinflammatory cytokine production [63, 64]. Specifically, the adenosine/Treg-mediated suppression of CD4+ T cells inhibits interleukin (IL)-2 and interferon-γ release as well as gag-stimulated CD8+ T-cell cytotoxic activity [65–67]. Antibodies that block CD39 activity inhibit Treg-mediated suppression of CD8+ T-cell cytokine production, suggesting that adenosine metabolism is integral in the suppressive effects of Tregs in HIV infection [48]. Therefore, although HIV infection is associated with a persistent immunooactivated state, local enhanced production of adenosine by Treg cells may mediate inappropriate immune tolerance.

IMPACT OF ADENOSINE SIGNALING ON INFLAMMATION AND COMORBIDITIES IN TREATED HUMAN IMMUNODEFICIENCY VIRUS

Despite the extended survival of PWH on ART, virally suppressed individuals experience a greater rate of age-associated non-AIDS events compared with PWOH, and this is a believed to be due to higher levels of inflammation [3]. Multiple factors contribute to this persistent inflammation. We have previously shown that PWH, regardless of viremia level or CD4+ T-cell reconstitution, have lower frequencies of CD4+ T cells expressing the rate-limiting enzyme CD73 and that CD4+CD73+ T-cell frequencies are associated with lower T-cell activation and C-reactive protein levels [49]. Likewise, Tóth et al [50] showed decreased frequencies of CD8+ T cells expressing CD73, and this correlated with immune activation and T-cell exhaustion. These findings suggest that alterations in the adenosine pathway are playing an important role in chronic HIV-associated inflammation.

An important factor contributing to the persistent inflammation in PWH is microbial translocation resulting from the
Table 1. Summary of Findings on the Adenosine Pathway and HIV Infection

| Reference               | Study Population                                      | Endpoint                                                                 | Major Findings                                                                                     |
|-------------------------|-------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Hixson et al [40]       | In vitro; murine clones expressing human CD26, CD4, and CXCR4 | Investigation of gp120-induced inhibition of ADA binding to human CD26 | • Soluble gp120 and HIV particles able to inhibit ADA-CD26 binding                                  |
|                         |                                                       |                                                                           | • CXCR4 cells enhanced gp120 inhibitory effects                                                    |
|                         |                                                       |                                                                           | • CXCR4 cells dependent on CD4 expression for inhibition                                           |
| Blanco et al [40]       | In vitro; primary human monocytes                      | Adenosine receptor influence on HIV Tat-induced intracellular calcium and TNF-α production | • A2R activation inhibited Tat-induced calcium release, and reduction of intracellular calcium inhibited Tat-α production in monocytes |
|                         |                                                       |                                                                           | • Inhibitory actions of adenosine receptors relied on protein phosphatase activity                  |
| Fotheringham et al [41] | In vitro; PC12 cells and rat cerebellar granule neuron cultures | Neuroprotective potential of A1 receptor activation against HIV Tat-induced toxicity | • A1R activation suppressed the increase in calcium and nitric oxide mediated by HIV Tat protein       |
|                         |                                                       |                                                                           | • A2R inhibition of inducible nitric-oxide synthase expression dependent on NFκB                    |
|                         |                                                       |                                                                           | • Activation of A2R displayed protection against Tat-induced apoptosis in PC12 cells and cerebellar granule cells |
| Pingle et al [42]       | In vitro; human A1R-expressing T cells                 | Functional inspection of the suppressive abilities of Tregs including extracellular adenosine formation | • Treg suppression occurred through gap junctions via a CAMP-dependent mechanism that activated protein kinase A in conventional T cells |
|                         |                                                       |                                                                           | • CD39 expression on Treg also played an important role during suppression                         |
| By et al [43]           | In vitro; CEM cells, a CD4+ human T lymphoma cell line expressing A2R, CXCR4, and CCR5 | Analysis of the influence of an agonist-like monoclonal antibody to A2R, Adonis, on CD4+CEM T cells | • Adonis assisted activation of A2AR and inhibited CEM cell growth                                   |
|                         |                                                       |                                                                           | • A2R upregulation reduced CXCR4 and CCR5 expression without altering CD4 expression on CEM cells   |
| Moreno-Fernandez et al [44] | Ex vivo; PBMCs from HIV+ participants | Functional inspection of the suppressive abilities of Tregs including extracellular adenosine formation | • ADA increased T-cell proliferation and positively correlated with CD4+ percentage and count while negatively correlated with viral load |
|                         |                                                       |                                                                           | • HIV reduced ADA-induced cytokine production (IFN-γ, IL-6, and IL10) in T cells                     |
|                         |                                                       |                                                                           | • gp120 impaired ADA-CD26 interaction in HIV                                                        |
| Martinez-Navio et al [45] | Ex vivo; 36 HIV+ and 10 HIV- participants | Exploration of the influence of HIV on ADA costimulation in T cells | • ADA-induced enhancement of CD4+ and CD8+ T-cell proliferation                                    |
|                         |                                                       |                                                                           | • ADA increased cytokine production (IFN-γ, TNF-α, and IL6) to promote a Th1 response to improve T helper and CTL responses |
| Climent et al [46]      | Ex vivo; 8 HIV+; HIV- participants                    | Measurement of the immunologic usefulness of ADA as an adjuvant in HIV dendritic cell-based therapeutic vaccines | • ADA expression on CD8+ T lymphocytes was lost after successive cultures                           |
|                         |                                                       |                                                                           | • CD8+CD28+ T lymphocytes that are ADA+ had greater telomerase activity than ADA                    |
|                         |                                                       |                                                                           | • Lack of ADA expression subjected CD8+ T lymphocytes to prolonged adenosine exposure, which accelerated senescence and loss of CD28 expression |
| Parish et al [47]       | Ex vivo; PBMCs from HIV+ participants                 | Investigation of the role of ADA on replicative senescence in human CD8+ T cells | • ADA expression on CD8+ T lymphocytes was lost after successive cultures                           |
|                         |                                                       |                                                                           | • CD8+CD28+ T lymphocytes that are ADA+ had greater telomerase activity than ADA                    |
|                         |                                                       |                                                                           | • Lack of ADA expression subjected CD8+ T lymphocytes to prolonged adenosine exposure, which accelerated senescence and loss of CD28 expression |
| Nikolova et al [48]     | Ex vivo; 39 HIV+, c-ART naive; 39 HIV-, c-ART stable; 25 HIV+ participants | Examination of the CD39/adenosine axis involvement in the pathogenesis and progression of HIV | • Downregulation of CD39 expression on Treg caused a higher CD8+ T-cell proliferation and cytokine production in HIV vs HIV+ individuals |
|                         |                                                       |                                                                           | • Higher level of A2AR expression on untreated HIV+ individuals, which caused a higher susceptibility to CD39/adenosine-mediated inhibition |
|                         |                                                       |                                                                           | • In HIV+ participants, CD39+ Treg positively correlated with immune activation and inversely with CD4+ T-cell absolute counts |
|                         |                                                       |                                                                           | • A CD39 gene polymorphism, causing lower levels of expression, associated with LTNPs and may indicate slower progression of HIV+1 disease |
| Schuler et al [49]      | Ex vivo; 36 HIV+ and 10 HIV- participants             | Examination of adenosine-induced immunomodulation and CD4+CD73+ T-cell involvement in HIV-associated immune activation | • Absolute numbers of CD4+CD73+ T cells are lower in HIV+ individuals compared to HIV− regardless of viral suppression |
|                         |                                                       |                                                                           | • Absolute numbers of CD4+CD73+ T cells inversely correlated with activated CD4+ T cells, activated CD8+ T cells, and plasma CRP in HIV− individuals |
|                         |                                                       |                                                                           | • Circulating CD4+CD39+ T cells frequency did not correlate with the frequency of activated CD4+ or CD8+ T cells or with the plasma CRP levels |
|                         |                                                       |                                                                           | • CD4+ T cells require the presence of both CD4+CD39+ and CD4+CD73+ T cells to hydrolyze exogenous ATP to adenosine |
|                         |                                                       |                                                                           | • Exogenous adenosine decreases in the percentage of cytokine-expressing CD4+ T cells               |
| Tóth et al [50]         | Ex vivo; 95 HIV+ and 27 HIV- participants             | Immunophenotypic analysis of T-cell populations were compared across 5 groups: health controls, ECs, LTNPs, ART patients, and viremic patients | • In HIV+ individuals, %CD73+ cells was significantly lower in CD8+ T cells and CD4+ non-Tregs compared with HIV− individuals |
|                         |                                                       |                                                                           | • Among the HIV+ participants, ECs and ART-treated participants showed the highest percentages of CD73+ cells |
|                         |                                                       |                                                                           | • Viremic participants displayed the lowest expression levels of CD73+, followed by LTNPs          |
| Reference          | Study Population                                                                 | Endpoint                                                                                   | Major Findings                                                                                     |
|-------------------|----------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| Menkova-Garnier et al [51] | Ex vivo; 16 HIV+ IRs; 16 HIV+ INRs; 18 HIV− participants                         | Limiting dilution assays of circulating CD34⁺ hematopoietic progenitor cells; frequency of recent thymic emigrants (RTEs), defined as CD31⁺CD27⁺CCR7⁺CD45RA⁺CD4⁺ cells; RT-qPCR analysis of FAS, P2X7, and CD73, mRNA levels in purified CD34⁺ cells; transcriptomic analysis of CD3⁺ cells in HIV IRs versus INRs | • There was no difference in the frequency of CD34⁺ cells between the 3 groups  
• The T-cell potential of CD34⁺ cells was significantly lower in INRs compared to HIV- participants and IRs  
• P2X7 was more strongly expressed in INRs than in IRs and HIV+ participants  
• CD37 expression was undetectable in all the INRs studied  
• P2X7 inhibition with PPAD significantly improved the potential of CD34⁺ cells from INRs to differentiate into T cells |
| He et al [5]      | In vivo; 14 PTM (pathogenic SIV host) and 15 AGM (nonpathogenic SIV host)        | Changes of markers related to ADO production (CD39 and CD73) and breakdown (CD26 and ADO deaminase) on T cells from blood, lymph nodes, and intestine after SIV acute infection | • Coexpression of CD39 and CD73 was low in circulating CD4⁺ Tregs and CD8⁺ Tregs in both AGMs and PTMs before infection  
• Coexpression of CD39 and CD73 was highest in intestinal Treg cells and significantly higher in AGMs compared with PTMs  
• Intestinal levels of adenosine increased during acute SIV infection in AGMs but not in PTMs |

**Abbreviations:** ADA, adenosine deaminase; ADO, adenosine; AGM, African green monkeys; ART, antiretroviral therapy; ATP, adenosine triphosphate; cAMP, 3'5'-cyclic monophosphate; c-ART, combination ART; CRP, C-reactive protein; CTL, cytotoxic T lymphocyte; EC, elite controllers; HIV, human immunodeficiency virus; IFN, interferon; IL, interleukin; INR, immunological nonresponder; IR, immunological responder; LTNP, long-term nonprogressor; mRNA, messenger ribonucleic acid; PBMC, peripheral blood mononuclear cell; PTM, pigtail macaques; SIV, simian immunodeficiency virus; RT-qPCR, quantitative reverse-transcription polymerase chain reaction; TNF, tumor necrosis factor; Treg, regulatory T cells.
From our current knowledge of the adenosine pathway, focusing on the role of adenosine as an anti-inflammatory agent could prove beneficial in developing safe and effective interventions in clinical settings. However, although chronic immunoactivation has an integral role in HIV-associated chronic conditions, local immunosuppression plays a key role in cancer risk and viral persistence. Although ART has reduced the mortality of AIDS-related cancers [97], PWH still experience accelerated aging and other risk factors for cancer diagnoses [98]. Long-term immunosuppression is likely the main contributor to non-AIDS-defining cancers [99, 100]. Enhanced adenosine activation in tumor microenvironments generates an immunosuppressant environment that supports tumor growth and evasion from T-cell immune defense [101]. Therefore, modulating adenosine activation in PWH, who are at risk for both solid and liquid malignancies, should be closely monitored.

Viruses that are commonly comorbid with HIV can also upregulate the expression and activity of CD39 and CD73 to facilitate infection [102, 103]. Endothelial cells infected with cytomegalovirus demonstrate an increase in local adenosine production due to the upregulation of both ectonucleotidases [102]. This is thought to facilitate viral entry into target cells by creating a locally immunosuppressive environment. In addition, compared with people with resolved hepatitis B virus (HBV) infection, HBV carriers have higher proportions of Tregs, and increase proportions of circulating CD39+ Tregs correlated with serum viral load, thus, suggesting that CD39+ Tregs contribute to chronic viral persistence [103].

Finally, modifying the adenosine pathway can have important implications on quality of life among PWH. Adenosine is a well-established sleep regulatory substance, and enhanced extracellular concentrations in the brain are associated with sleep deprivation and promotion of sleep, particularly via stimulation of A1 and A2A receptors [104]. Indeed, caffeine, an adenosine antagonist, is commonly used to thwart sleepiness in the general population [105]. Sleep disturbances are highly prevalent among PWH and, therefore, they may be especially vulnerable to worsened fatigue [106]. Enhancing adenosine activation may facilitate insomnia and nocturnal sleep quality among PWH. However, adenosine activation may promote daytime sleepiness and fatigue as well. Alternatively, changes in sleep patterns have been demonstrated to augment P2X7 and A2a receptor expression on circulating leukocytes [107]; this suggests that modifying sleep behavior may be a novel nonpharmacologic mechanism to alter purinergic signaling in PWH.

**POTENTIAL OF PHARMACOTHERAPIES**

There is an understandably heightened interest in developing effective pharmacotherapies to reduce the incidence of non-AIDS-related comorbidities that lead to early mortality in PWH. Targeting the purinergic signaling pathway to shift the balance away from proinflammatory P2 activation towards anti-inflammatory activation of adenosine receptors is an attractive model to test pharmacotherapeutics. For example, A2A receptors are a critical part in the negative feedback loop of limiting and inhibiting inflammatory responses, providing a rationale to develop A2A receptor-targeted therapeutics to either inhibit or enhance immune responses [38, 108, 109]. There has been emerging literature on pharmacological approaches that target purinergic signaling in various ways to reconstitute the subsequent immune damage of HIV-1 infection [110, 111]. This review focuses on potential therapies to reduce inflammation and promote viral clearance (Figure 2).

Investigation into several potential therapies to curb chronic inflammation in ART-treated PWH and show promising preliminary results [112]. Given that T-cell expression of CD73 is reduced among PWH, attempts have been made to assess whether modulating the adenosine signaling pathway may decrease the persistent chronic inflammatory profile experienced in PWH. In a double-blind, placebo-controlled study, we randomized 40 ART-controlled PWH to 12 weeks of dipyridamole versus placebo, followed by 12 weeks of open-label dipyridamole [113]. Dipyridamole is a nucleoside transport inhibitor and phosphodiesterase 3 inhibitor used clinically in patients with a history of peripheral vascular disease and stroke patients to prevent future thrombotic events. It increases extracellular adenosine by blocking ENTs and preventing transport of adenosine intracellularly down its concentration gradient [114, 115]. Initial data showed that dipyridamole decreased CD8+ T-cell activation in the treatment arm versus placebo arm. In pooled analyses, after 12 weeks of dipyridamole, there was a significant decrease in CD4+ T-cell activation and a trend toward decreased CD8+ T-cell activation in blood [113]. In a substudy, we collected rectosigmoid biopsies from 18 participants to further assess the effect of dipyridamole on mucosal immune cells. Those receiving dipyridamole had (1) a median 70.2% decrease from baseline in the Treg population and (2) an 11.3% increase in CD8+ T cells. There were also trends towards decreased CD4+ T-cell activation and CD8+ T-cell activation [116]. Because the population of Tregs increased in response to heightened inflammation, these data suggest that there is a decrease in gut inflammation that obviates a compensatory Treg response.

Modulating ectonucleotidase activity, particularly CD39 and CD73 activity, is an attractive therapeutic target to reduce proinflammatory extracellular ATP concentrations in favor of anti-inflammatory adenosine. Methotrexate and sulfasalazine, immunosuppressants commonly used in IBD, may be partially effective in treating IBD by enhanced CD73 production of adenosine [117]. Among PWH, although low doses of methotrexate had no effect on systemic inflammatory endothelial markers, there were improvements in brachial artery ultrasound measurements, which may indicate favorable vasculature changes...
Rosuvastatin, typically used to treat high cholesterol and triglyceride levels, can also increase extracellular adenosine formation via upregulation of CD73, and it has shown in vivo protection against inflammation [120–122]. The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is an ongoing, prospective, randomized placebo-controlled clinical trial of a pitavastatin strategy for the primary CVD prevention among PWH [123]. In addition to informing the field on the efficacy of statin strategy among PWH, it includes multiple measurements of plaque stability, immune activation, and inflammation [124]. This trial may provide valuable insights on the role of statins in modifying purinergic metabolism.

Figure 2. Pharmacologic targets to target adenosine metabolism in human immunodeficiency virus infection. Sites and available therapeutics that decrease purinergic 2 (P2) receptor activity and promote extracellular adenosine and adenosine 2A (A2A) receptor activation are shown. A2A receptor, adenosine 2A receptor; ADA, adenosine deaminase; ADP, adenosine diphosphate; AMP, adenosine monophosphate; ATP, adenosine triphosphate; ENT, equilibrative nucleoside transporter; P2Y receptor, purinergic 2Y receptor.

Selectively inhibiting P2Yγ receptor expression with small interfering ribonucleic acids reduces the HIV-induced inflammatory response and cell death [125, 126]. Inhibiting P2X receptors to restore T-cell differentiation from CD34+ hematopoietic progenitor cells could be a potential strategy in PWH, who experience reduced immune recovery while on ART, to regenerate new T-cell populations [51]. Due to the ubiquitous nature of purinergic receptors, there should be a narrowed focus on refining the characterization of cellular patterns and molecular control of expression of crucial enzymes in the purinergic signaling pathway to minimize unwanted side effects. It is important to understand receptor regulation to design and improve purinergic receptor strategies to effectively prevent accelerated aging and control systemic inflammation in PWH.

CONCLUSIONS

Although ART is effective in viral suppression and prolonging the development of AIDS, the concern lies in patient susceptibilities to morbidity and early mortality of age-associated diseases due to immunological dysfunction caused by HIV. Adenosine agonists provide immune advantage by inhibiting T-cell effector function, in conjunction with Tregs, to reduce the chronic immune activation and dysfunction seen in PWH. However, although enhancing CD39 and CD73 activity may improve inflammation and immunoactivation-related comorbidities in HIV, modulating ectonucleotidase activity is a double-edged sword. The adenosine/Treg axis can be detrimental by suppressing HIV-specific immune responses. Additional studies are necessary to determine the proper balance between controlling inflammation but still allowing the generation of an effective immune response against the virus. Novel and innovative strategies targeting these 2 contrasting functions of the adenosine pathway can lead to a decreased risk.
for non-AIDS-associated chronic disease and, at the same time, target viral persistence.

Acknowledgments

Author contributions. E. A. H. and P. V. B. wrote the initial draft of the manuscript. E. A. H., P. V. B., E. K. J., and B. J. M. were all involved in writing the manuscript and revisions. All authors are affiliated with the University of Pittsburgh and have reviewed and approved the following manuscript. Each author has contributed to the development of this manuscript.

Financial support. This research was funded by the following: NIH/ NHLBI Grant 5T32 HL082610-13 (to P. V. B.) The American Thoracic Society ASPIRE Grants (to P. V. B.), NIH NIAID Grants U01 AI10410 and R01 HL142118 (to B. J. M.), and internal funding from the Department of Medicine, University of Pittsburgh (to B. J. M.).

Potential conflicts of interest. B. J. M. has received research funding paid to the institution from GILEAD sciences. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Cai CW, Sereti I. Residual immune dysfunction under antiretroviral therapy. Semin Immunol 2021;101:671.
2. Elvstam O, Marrone G, Medstrand P, et al. All-cause mortality and serious non-AIDS events in adults with low-level human immunodeficiency virus viremia during combination antiretroviral therapy: results from a Swedish Nationwide Observational Study. Clin Infect Dis 2021;72:2079–86.
3. Babu H, Ambikan AT, Gabriel EE, et al. Systemic inflammation and the increased risk of inflammation-aging and age-associated diseases in people living with HIV on long term suppressive antiretroviral therapy. Front Immunol 2019;10:1965.
4. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: Workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008;47:542–53.
5. He T, Brocca-Cofano E, Gillespie DG, et al. Critical role for the adenosine pathway in controlling simian immunodeficiency virus-related immune activation and inflammation in gut mucosal tissues. J Virol 2015;89:9616–30.
6. Pausos DE, Bernardes VM, da Silva IJG, et al. Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection. Purinergic Signal 2018;14:309–20.
7. Milne GR, Palmer TM. Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. ScientificWorldJournal 2011;11:320–39.
8. Kumar V, Sharma A. Adenosine: an endogenous modulator of innate immune system with therapeutic potential. Eur J Pharmacol 2009;616:7–15.
9. Rayah A, Kandelopoulos JM, Di Virgilio F. P2 receptors and immunity. Microbes Infect 2012;14:1254–62.
10. Jarvis ME, Khakk BS. ATP-gated P2X cation-channels. Neuropharmacology 2009;56:208–15.
11. Jacobson KA, Delcado EG, Gachet C, et al. Update of P2Y receptor pharmacology. JUPHAR Review 27. Br J Pharmacol 2020;177:2413–33.
12. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 2000;362:299–309.
13. Alam MS, Costales MG, Cavanaugh C, Williams K. Extracellular adenosine generation in the regulation of pro-inflammatory responses and pathogen colonization. Biomolecules 2015;5:775–92.
14. Coleman MS, Hutton J. Micromethod for quantitation of adenosine deaminase activity in cells from human peripheral blood. Biochem Med 1975;13:46–55.
15. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5:247–64.
16. Dhallal AK, Shyrock JC, Shreenivas R, Belardelli L. Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr Top Med Chem 2003;3:369–85.
17. Panter E, Corinti S, Idzko M, et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 2003;101:3985–90.
18. Fortin A, Harbour D, Fernandes M, et al. Differential expression of adenosine receptors in human neutrophils: up-regulation by specific Th1 cytokines and lipopolysaccharide. J Leukoc Biol 2006;79:574–85.
19. Zhang Y, Palmblad J, Fredholm BB. Biphasic effect of ATP on neutrophil functions mediated by P2U and adenosine A2A receptors. Biochem Pharmacol 1996;51:957–65.
adenosine deaminase-induced costimulation of T-cell activation. Immunology 2009; 128:391–404.
46. Climenti N, Martinez-Navio JM, Gil C, et al. Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV. Immunol Cell Biol 2009; 87:634–9.
47. Parish ST, Kim S, Sekhon RK, et al. Adenosine deaminase modulation of tollerance activity and replicative senescence in CD8 T lymphocytes. J Immunol 2010; 184:287–94.
48. Nikolova M, Carriere M, Jenabian MA, et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 2011; 7:e1002110.
49. Schuler PJ, Macatangay BJ, Saze Z, et al. CD4+CD73+ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. AIDS 2013; 27:1545–55.
50. Toth I, Le AQ, Hartjen P, et al. Decreased frequency of CD73+CD38+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion. J Leukoc Biol 2013; 94:531–61.
51. Menkova-Garnier I, Hocini H, Foucat E, et al. PDZ7 Receptor inhibition improves CD4 T-cell differentiation in HIV-infected immunological nonresponders on c-ART. PLoS Pathog 2016; 12:e1005571.
52. Swartz TH, Esposito AM, Durham ND, et al. PD2-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection. J Virol 2014; 88:11504–15.
53. Graziano F, Desdouts M, Garzetti L, et al. Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages. Proc Natl Acad Sci U S A 2015; 112:E2265–73.
54. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2016; 62:141–55.
55. Deeks SG, Verdin E, McCune JM. Immunosenescence and HIV. Curr Opin Immunol 2012; 24:501–6.
56. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4+CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10:e1004078.
57. Gupta PK, Godec J, Wolski D, et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog 2015; 11:e1005177.
58. Dierks P, Wrobelwski R, Eberhard JM, et al. Brief report: increased frequency of CD39+ CD56bright natural killer cells in HIV-1 infection correlates with immune activation and disease progression. J Acquir Immune Defic Syndr 2017; 74:467–72.
59. Song JW, Huang HH, Zhang C, et al. Expression of CD39 is correlated with HIV DNA levels in naive tregs in chronically infected ART naive patients. Front Immunol 2016; 7:216.
60. Rueda CM, Jackson CM, Chougnet CA. Regulatory T-cell-mediated suppression of conventional T-cells and dendritic cells by different aMP intracellular pathways. Front Immunol 2016; 7:216.
61. Deaglio S, Dwyer KM, Gao W, et al. Adenosine deaminase generation catalyzed by CD39 and CD73 expressed on dendritic cells and dendritic cell precursors. Front Immunol 2017; 8:3292.
62. Ouyang X, Ghani A, Malik A, et al. Adenosine is required for sustained immune activation and disease progression. J Acquir Immune Defic Syndr 2017; 74:1003–14.
63. Sparks DL, Chatterjee C. Purinergic signaling, dyslipidemia and immunodeficiency disease. Cell Physiol Biochem 2012; 30:1333–9.
64. Teixeira GP, Faria RX. Influence of purinergic signaling on glucose transporters: A possible mechanism against insulin resistance? Eur J Pharmacol 2021; 892:173743.
65. Garcia-Hernández MH, Portales-Cervantes L, Cortez-Espinosa N, et al. Expression and function of P2X7 receptor and CD39/ENTPD1 in patients with type 2 diabetes and their association with biochemical parameters. Cell Immunol 2011; 268:135–43.
66. Modic S, Rossi C, Chiarugi M, et al. Adenosine regulates PDZ7 receptors expression: a role in modulating inflammatory response in subjects with metabolic syndrome? Atherosclerosis 2011; 219:552–8.
67. Chatterjee C, Sparks DL. Extracellular nucleotides inhibit insulin receptor signaling, stimulate autophagy and control lipoprotein secretion. PLoS One 2012; 7:e36916.
68. Zhang Y, Eccelberger CM, Lesniewski LA, et al. PD27 receptor promotes high-fat diet-induced obesity. Front Endocrinol (Lausanne) 2020; 11:341.
69. Park LS, Tate JP, Sigel K, et al. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012. AIDS 2016; 30:1795–806.
97. Shiels MS, Engels EA. Evolving epidemiology of HIV-associated malignancies. Curr Opin HIV AIDS 2017; 12:6–11.
98. Hernández-Ramírez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1997 to 2012: a population-based, registry-linkage study. Lancet HIV 2017; 4:e495–504.
99. Galabov AS, Mastikova M. Dipyridamole is an interferon inducer. Acta Virol 1982; 26:137–47.
100. Newby AC. How does dipyridamole elevate extracellular adenosine concentration? Predictions from a three-compartment model of adenosine formation and inactivation. Biochem J 1986; 237:845–51.
101. Mallarino-Haeger C, Abebe KZ, Jackson EK, et al. Dipyridamole decreases gut mucosal regulatory T cell frequencies among people with HIV on antiretroviral therapy. J AIDS 2020; 85:665–9.
102. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med 2012; 367:2322–33.
103. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces gut mucosal regulatory T cell frequencies among people with HIV on antiretroviral therapy. J Infect Dis 2019; 221:1598–1606.